Online inquiry

IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1392MR)

This product GTTS-WQ1392MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1A&IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000575.5; NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552; 3553
UniProt ID P01583; P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1392MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ2885MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ5823MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ8483MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ15043MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SRF-231
GTTS-WQ4211MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ4849MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ8186MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW